Blood screening for preclinical Alzheimer’s disease in a British birth cohort


  • In a theoretical cohort prevalence range of 10–50% amyloid positron emission tomography (PET) positivity, mass spectrometry amyloid-β1–42/1–40 measures would consistently reduce numbers of individuals proceeding to scans, showing greater efficiency and reduced cost.

Why this matters

  • Advances in Alzheimer’s disease (AD) research have yielded multiple potential blood-based detection techniques for the AD marker, amyloid-β during the preclinical disease stage; however, findings regarding their efficiency have been mixed.

  • The efficiency of liquid chromatography-mass spectrometry (LC-MS) for identifying plasma AD markers may lead to increased screening and identification of individuals at risk of developing clinical AD, resulting in significant time and cost saving, whilst allowing earlier intervention for at-risk populations.